Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 13 | 2018 | 239 | 2.930 |
Why?
|
| Rats | 41 | 2020 | 1604 | 2.130 |
Why?
|
| Conditioning, Operant | 7 | 2014 | 96 | 1.790 |
Why?
|
| Rats, Inbred F344 | 23 | 2018 | 125 | 1.740 |
Why?
|
| Heroin | 8 | 2011 | 14 | 1.740 |
Why?
|
| Cocaine | 12 | 2023 | 264 | 1.720 |
Why?
|
| Spinal Nerves | 8 | 2020 | 65 | 1.500 |
Why?
|
| Reaction Time | 4 | 2018 | 121 | 1.420 |
Why?
|
| Animals | 47 | 2020 | 7297 | 1.410 |
Why?
|
| Hyperalgesia | 10 | 2020 | 88 | 1.400 |
Why?
|
| Receptors, Opioid, mu | 5 | 2015 | 51 | 1.380 |
Why?
|
| Choice Behavior | 3 | 2020 | 83 | 1.300 |
Why?
|
| Attention | 3 | 2018 | 83 | 1.280 |
Why?
|
| Pain Measurement | 9 | 2018 | 364 | 1.270 |
Why?
|
| Pain, Postoperative | 7 | 2018 | 174 | 1.270 |
Why?
|
| Self Administration | 17 | 2020 | 296 | 1.260 |
Why?
|
| Brain | 7 | 2020 | 930 | 1.220 |
Why?
|
| Behavior, Animal | 10 | 2017 | 264 | 1.190 |
Why?
|
| Photic Stimulation | 2 | 2017 | 155 | 1.080 |
Why?
|
| Nucleus Accumbens | 8 | 2018 | 92 | 1.060 |
Why?
|
| Neuralgia | 5 | 2019 | 48 | 1.000 |
Why?
|
| Morphine | 5 | 2012 | 57 | 0.900 |
Why?
|
| Electric Stimulation | 3 | 2012 | 102 | 0.890 |
Why?
|
| Self Stimulation | 4 | 2014 | 4 | 0.820 |
Why?
|
| Male | 42 | 2020 | 17807 | 0.810 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 5 | 2015 | 24 | 0.810 |
Why?
|
| Injections, Spinal | 8 | 2013 | 124 | 0.810 |
Why?
|
| Pain | 6 | 2023 | 282 | 0.800 |
Why?
|
| Reward | 2 | 2011 | 63 | 0.780 |
Why?
|
| Neurons | 3 | 2018 | 394 | 0.760 |
Why?
|
| Pain Threshold | 7 | 2020 | 95 | 0.740 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2018 | 641 | 0.740 |
Why?
|
| Analgesics | 4 | 2017 | 126 | 0.730 |
Why?
|
| Naltrexone | 5 | 2011 | 38 | 0.730 |
Why?
|
| Laparotomy | 5 | 2011 | 32 | 0.730 |
Why?
|
| Ventral Tegmental Area | 5 | 2018 | 31 | 0.690 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2016 | 40 | 0.680 |
Why?
|
| Cues | 2 | 2017 | 67 | 0.650 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 69 | 0.640 |
Why?
|
| Abdominal Pain | 1 | 2017 | 40 | 0.610 |
Why?
|
| Spinal Cord | 6 | 2018 | 139 | 0.590 |
Why?
|
| Heroin Dependence | 2 | 2007 | 4 | 0.580 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2020 | 747 | 0.570 |
Why?
|
| Arvicolinae | 1 | 2015 | 2 | 0.550 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 980 | 0.540 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2006 | 39 | 0.540 |
Why?
|
| Motor Activity | 4 | 2014 | 310 | 0.530 |
Why?
|
| Narcotics | 4 | 2007 | 18 | 0.520 |
Why?
|
| Sex Characteristics | 1 | 2015 | 167 | 0.510 |
Why?
|
| Ligation | 4 | 2019 | 55 | 0.500 |
Why?
|
| Inflammation | 2 | 2017 | 507 | 0.500 |
Why?
|
| Foot Injuries | 1 | 2014 | 11 | 0.490 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 97 | 0.490 |
Why?
|
| Narcotic Antagonists | 4 | 2011 | 50 | 0.490 |
Why?
|
| Methadone | 3 | 2011 | 12 | 0.480 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2020 | 120 | 0.460 |
Why?
|
| Nasal Decongestants | 1 | 2013 | 2 | 0.460 |
Why?
|
| Tachycardia, Ventricular | 1 | 2013 | 14 | 0.450 |
Why?
|
| Clonidine | 3 | 2011 | 60 | 0.450 |
Why?
|
| Methamphetamine | 1 | 2013 | 18 | 0.450 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2012 | 8 | 0.430 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 77 | 0.400 |
Why?
|
| Dopamine | 3 | 2015 | 226 | 0.380 |
Why?
|
| Amygdala | 1 | 2011 | 60 | 0.380 |
Why?
|
| Isothiocyanates | 2 | 2008 | 6 | 0.380 |
Why?
|
| Globus Pallidus | 2 | 2007 | 8 | 0.370 |
Why?
|
| Food | 3 | 2019 | 41 | 0.360 |
Why?
|
| Cyclooxygenase 2 | 2 | 2006 | 50 | 0.350 |
Why?
|
| Electrodes, Implanted | 3 | 2014 | 41 | 0.330 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 4 | 2015 | 18 | 0.330 |
Why?
|
| Cannabinoids | 2 | 2020 | 39 | 0.320 |
Why?
|
| Ketorolac | 2 | 2005 | 24 | 0.320 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 50 | 0.310 |
Why?
|
| Exploratory Behavior | 2 | 2005 | 30 | 0.310 |
Why?
|
| Mechanoreceptors | 3 | 2020 | 37 | 0.310 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2018 | 80 | 0.300 |
Why?
|
| Infusions, Intravenous | 4 | 2011 | 85 | 0.300 |
Why?
|
| Drug Tolerance | 1 | 2007 | 36 | 0.300 |
Why?
|
| Transferases | 1 | 2006 | 1 | 0.300 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2006 | 6 | 0.290 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 12 | 0.290 |
Why?
|
| Receptors, Opioid, delta | 1 | 2006 | 17 | 0.290 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 23 | 0.290 |
Why?
|
| Cocaine-Related Disorders | 2 | 2015 | 106 | 0.280 |
Why?
|
| Spinal Cord Injuries | 1 | 2006 | 32 | 0.280 |
Why?
|
| Hypertension | 1 | 2013 | 906 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2019 | 74 | 0.270 |
Why?
|
| Abdomen | 1 | 2005 | 42 | 0.260 |
Why?
|
| Neural Conduction | 2 | 2016 | 81 | 0.260 |
Why?
|
| Adenosine | 3 | 2011 | 41 | 0.250 |
Why?
|
| Time Factors | 8 | 2017 | 2001 | 0.240 |
Why?
|
| Acetylcholine | 1 | 2004 | 47 | 0.240 |
Why?
|
| Autoradiography | 3 | 2015 | 47 | 0.230 |
Why?
|
| Nociceptors | 2 | 2020 | 41 | 0.230 |
Why?
|
| Anesthesia | 1 | 2023 | 65 | 0.220 |
Why?
|
| Cyclohexanols | 2 | 2020 | 20 | 0.220 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 103 | 0.220 |
Why?
|
| Central Nervous System Stimulants | 1 | 2023 | 74 | 0.220 |
Why?
|
| Ganglia, Spinal | 2 | 2020 | 63 | 0.210 |
Why?
|
| Carbon Radioisotopes | 1 | 2020 | 20 | 0.190 |
Why?
|
| Microtubules | 1 | 2020 | 17 | 0.190 |
Why?
|
| Quinazolines | 1 | 2020 | 31 | 0.190 |
Why?
|
| Hydromorphone | 2 | 2011 | 4 | 0.180 |
Why?
|
| Food Preferences | 1 | 2020 | 35 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 87 | 0.180 |
Why?
|
| Fentanyl | 2 | 2011 | 33 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 172 | 0.170 |
Why?
|
| Drug Synergism | 3 | 2011 | 67 | 0.170 |
Why?
|
| Eating | 3 | 2015 | 73 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2014 | 454 | 0.160 |
Why?
|
| Action Potentials | 1 | 2018 | 174 | 0.160 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2017 | 33 | 0.150 |
Why?
|
| Alkylation | 2 | 2007 | 5 | 0.150 |
Why?
|
| Binding, Competitive | 2 | 2007 | 38 | 0.150 |
Why?
|
| Radioligand Assay | 2 | 2007 | 23 | 0.150 |
Why?
|
| Triazoles | 1 | 2016 | 14 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2006 | 80 | 0.140 |
Why?
|
| Pruritus | 1 | 2016 | 58 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2018 | 208 | 0.140 |
Why?
|
| Macaca mulatta | 4 | 2020 | 322 | 0.140 |
Why?
|
| Sulfur Radioisotopes | 1 | 2015 | 9 | 0.140 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2015 | 13 | 0.140 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2015 | 4 | 0.140 |
Why?
|
| Neuroglia | 1 | 2015 | 29 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2015 | 32 | 0.140 |
Why?
|
| Circadian Rhythm | 2 | 2006 | 43 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2015 | 39 | 0.130 |
Why?
|
| Phenmetrazine | 1 | 2015 | 4 | 0.130 |
Why?
|
| Analgesia | 1 | 2015 | 33 | 0.130 |
Why?
|
| Microdialysis | 2 | 2006 | 33 | 0.130 |
Why?
|
| Stereotyped Behavior | 2 | 2005 | 14 | 0.130 |
Why?
|
| Echocardiography | 1 | 2015 | 140 | 0.130 |
Why?
|
| Norepinephrine | 1 | 2015 | 73 | 0.130 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 31 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2015 | 190 | 0.130 |
Why?
|
| Cognition | 1 | 2017 | 526 | 0.120 |
Why?
|
| Breast Cyst | 1 | 2013 | 2 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2013 | 92 | 0.110 |
Why?
|
| Physical Stimulation | 2 | 2016 | 84 | 0.110 |
Why?
|
| Oxycodone | 1 | 2011 | 7 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2015 | 666 | 0.100 |
Why?
|
| Corticosterone | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 20 | 0.100 |
Why?
|
| Amines | 1 | 2011 | 22 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2011 | 13 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2015 | 283 | 0.100 |
Why?
|
| Fever | 1 | 2011 | 56 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 107 | 0.100 |
Why?
|
| Pressure | 1 | 2011 | 54 | 0.100 |
Why?
|
| Humans | 6 | 2023 | 29093 | 0.090 |
Why?
|
| Microglia | 1 | 2010 | 48 | 0.090 |
Why?
|
| Protein Binding | 2 | 2008 | 199 | 0.090 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2008 | 19 | 0.080 |
Why?
|
| Nortropanes | 1 | 2008 | 2 | 0.080 |
Why?
|
| Tropanes | 1 | 2008 | 9 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 16 | 0.080 |
Why?
|
| Corpus Striatum | 1 | 2008 | 60 | 0.080 |
Why?
|
| Female | 3 | 2015 | 18164 | 0.080 |
Why?
|
| Alkylating Agents | 1 | 2007 | 4 | 0.080 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2008 | 96 | 0.080 |
Why?
|
| Macaca fascicularis | 2 | 2020 | 389 | 0.080 |
Why?
|
| Microinjections | 2 | 2004 | 33 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 73 | 0.070 |
Why?
|
| Sulfur Isotopes | 1 | 2006 | 2 | 0.070 |
Why?
|
| Theophylline | 1 | 2006 | 4 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2008 | 369 | 0.070 |
Why?
|
| Phosphatidylethanolamines | 1 | 2006 | 2 | 0.070 |
Why?
|
| Sensory Thresholds | 1 | 2006 | 26 | 0.070 |
Why?
|
| Nitrobenzenes | 1 | 2006 | 10 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2006 | 59 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2006 | 51 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 89 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2006 | 64 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2006 | 65 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 246 | 0.070 |
Why?
|
| Ileus | 1 | 2005 | 5 | 0.070 |
Why?
|
| Abdominal Muscles | 1 | 2005 | 6 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2005 | 30 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 24 | 0.070 |
Why?
|
| Bupivacaine | 1 | 2005 | 48 | 0.070 |
Why?
|
| Osteoclasts | 1 | 2005 | 22 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 86 | 0.060 |
Why?
|
| Sucrose | 1 | 2004 | 17 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2006 | 159 | 0.060 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2004 | 6 | 0.060 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2004 | 5 | 0.060 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2004 | 10 | 0.060 |
Why?
|
| Cholinergic Agents | 1 | 2004 | 6 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2004 | 16 | 0.060 |
Why?
|
| Oxidopamine | 1 | 2003 | 6 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 71 | 0.060 |
Why?
|
| Patients | 1 | 2023 | 46 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2014 | 37 | 0.060 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 16 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 196 | 0.050 |
Why?
|
| Middle Aged | 2 | 2013 | 10829 | 0.050 |
Why?
|
| Touch | 1 | 2020 | 35 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2006 | 3099 | 0.040 |
Why?
|
| Psychology | 1 | 2018 | 22 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 2017 | 10 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 2017 | 26 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2011 | 799 | 0.040 |
Why?
|
| Pyramidal Tracts | 1 | 2015 | 3 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 104 | 0.030 |
Why?
|
| Proton Pumps | 1 | 2014 | 7 | 0.030 |
Why?
|
| Neurofilament Proteins | 1 | 2014 | 11 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2014 | 52 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cardiology | 1 | 2015 | 72 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 71 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2014 | 80 | 0.030 |
Why?
|
| Emergency Medicine | 1 | 2015 | 117 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 469 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 787 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2011 | 19 | 0.030 |
Why?
|
| Immunization | 1 | 2011 | 28 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 30 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 2368 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 207 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 53 | 0.020 |
Why?
|
| Morphine Derivatives | 1 | 2005 | 3 | 0.020 |
Why?
|
| Prosencephalon | 1 | 2005 | 5 | 0.020 |
Why?
|
| Membranes | 1 | 2005 | 11 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2005 | 1 | 0.020 |
Why?
|
| Osteopetrosis | 1 | 2005 | 2 | 0.020 |
Why?
|
| Oxazines | 1 | 2005 | 2 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2005 | 3 | 0.020 |
Why?
|
| Cathepsins | 1 | 2005 | 3 | 0.020 |
Why?
|
| Xanthenes | 1 | 2005 | 4 | 0.020 |
Why?
|
| Chloride Channels | 1 | 2005 | 7 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2005 | 5 | 0.020 |
Why?
|
| Macrolides | 1 | 2005 | 8 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 11 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2005 | 13 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2005 | 15 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2005 | 63 | 0.020 |
Why?
|
| Tetrazoles | 1 | 2005 | 71 | 0.020 |
Why?
|
| Family Health | 1 | 2005 | 78 | 0.020 |
Why?
|
| Ovary | 1 | 2005 | 54 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2005 | 87 | 0.020 |
Why?
|
| Bone Density | 1 | 2005 | 182 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 188 | 0.010 |
Why?
|
| Neostriatum | 1 | 2003 | 21 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 519 | 0.010 |
Why?
|
| Reinforcement Schedule | 1 | 2003 | 60 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 629 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 373 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 466 | 0.010 |
Why?
|
| Adult | 1 | 2005 | 8420 | 0.010 |
Why?
|